Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Income from Continuing Operations (2016 - 2025)

Tvardi Therapeutics' Income from Continuing Operations history spans 13 years, with the latest figure at 7275000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 31.82% to 7275000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 23680000.0, a 55.17% increase, with the full-year FY2025 number at 25373000.0, up 64.2% from a year prior.
  • Income from Continuing Operations hit 7275000.0 in Q4 2025 for Tvardi Therapeutics, down from 5527000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for TVRD hit a ceiling of 1013000.0 in Q3 2021 and a floor of 33382000.0 in Q4 2021.
  • Historically, Income from Continuing Operations has averaged 18698750.0 across 5 years, with a median of 23573000.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 93.86% in 2021 and later plummeted 2253.9% in 2022.
  • Tracing TVRD's Income from Continuing Operations over 5 years: stood at 33382000.0 in 2021, then increased by 6.22% to 31307000.0 in 2022, then dropped by 4.15% to 32607000.0 in 2023, then skyrocketed by 67.28% to 10670000.0 in 2024, then surged by 31.82% to 7275000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TVRD at 7275000.0 in Q4 2025, 5527000.0 in Q3 2025, and 8492000.0 in Q2 2025.